Targeted, triggered drug delivery to tumor and biofilm microenvironments

Nanomedicine

Volumn 11, Issue 8, 2016, Pages 873-879

  Benoit, Danielle S W ^a,b   Koo, Hyun ^c  

^a University of Rochester   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

biofilm; extracellular matrix; microenvironment; nanomedicine; nanoparticles; tumor

Indexed keywords

ANTINEOPLASTIC AGENT; NANOCARRIER; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; NANOPARTICLE;

BIOFILM; CELL HYPOXIA; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; NOTE; PH; PRIORITY JOURNAL; SYNTHESIS; TUMOR MICROENVIRONMENT; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; MICROBIOLOGY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIA; BACTERIAL INFECTIONS; BIOFILMS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; NANOPARTICLES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84962169596     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0014     Document Type: Note

References (25)

1. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12(11), 991-1003 (2013).
2. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
3. Lebeaux D, Chauhan A, Letoffe S et al. pH-mediated potentiation of aminoglycosides kills bacterial persisters and eradicates in vivo bioflms. J. Infect. Dis. 210(9), 1357-1366 (2014).
4. Lebeaux D, Ghigo JM, Beloin C. Bioflm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev. 78(3), 510-543 (2014).
5. Torchilin V P. Multifunctional nanocarriers. Adv. Drug Del. Rev. 64, 302-315 (2012).
6. Upreti M, Jyoti A, Sethi P. Tumor microenvironment and nanotherapeutics. Transl. Cancer Res. 2(4), 309-319 (2013).
7. Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K. Lipid and polymer nanoparticles for drug delivery to bacterial bioflms. J. Control. Release 190607-623 (2014).
8. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196 (4), 395-406 (2012).
9. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial bioflms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2(2), 95-108 (2004).
10. Flemming HC, Wingender J. The bioflm matrix. Nat. Rev. Microbiol. 8(9), 623-633 (2010).
11. Koo H, Falsetta ML, Klein MI. The exopolysaccharide matrix: a virulence determinant of cariogenic bioflm. J. Dent. Res. 92 (12), 1065-1073 (2013).
12. Stewart PS, Franklin MJ. Physiological heterogeneity in bioflms. Nat. Rev. Microbiol. 6 (3), 199-210 (2008).
13. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11(17-18), 812-818 (2006).
14. Azzopardi EA, Ferguson EL, Thomas DW. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. J. Antimicrob. Chemother. 68(2), 257-274 (2013).
15. Barua S, Mitragotri S. Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today 9(2), 223-243 (2014).
16. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect: insights from the past decade. Pharmacol. Ther. 137(3), 318-330 (2013).
17. Schmaljohann D. Thermo-and pH-responsive polymers in drug delivery. Adv Drug Deliv. Rev. 58 (15), 1655-1670 (2006).
18. Wouters A, Pauwels B, Lardon F, Vermorken JB. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 12(6), 690-712 (2007).
19. 2 in abscesses, peritoneal fuid, and drainage fuid in the presence or absence of bacterial infection during and after abdominal surgery. Am. J. Surg. 166(1), 24-27 (1993).
20. Horev B, Klein MI, Hwang G et al. pH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral bioflm virulence. ACS Nano 9(3), 2390-2404 (2015).
21. Radovic-Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, Farokhzad OC. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano 6(5), 4279-4287 (2012).
22. Zhu YJ, Chen F. pH-responsive drug-delivery systems. Chem. Asian J. 10(2), 284-305 (2015).
23. Liu J, Huang Y, Kumar A et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 32(4), 693-710 (2014).
24. Thambi T, Deepagan VG, Yoon HY et al. Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials 35 (5), 1735-1743 (2014).
25. Perche F, Biswas S, Wang T, Zhu L, Torchilin VP. Hypoxia-targeted siRNA delivery. Angew. Chem. Int. Ed. Engl. 53(13), 3362-3366 (2014).